You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃森生物(300142.SZ):公司RQ3013Ⅲ期臨牀試驗數據尚未全部揭盲
格隆匯 05-22 07:38

格隆匯5月22日丨有投資者在投資者互動平台向沃森生物(300142.SZ)提問,“貴公司的新冠疫苗RQ3013大三期臨牀試驗,在入組完成後,預計多長時間後才揭盲?是所有入組人員一起揭盲,還是按照入組時間先後順序先入的先揭盲呢?有信心在新冠病毒第二波感染高峯前上市嗎?”

沃森生物回覆稱,公司RQ3013Ⅲ期臨牀試驗數據尚未全部揭盲, IIIb期臨牀試驗主要結果及III期效力臨牀試驗期中分析主要結果均已公吿。後續數據待滿足揭盲條件後會一併公吿。當前病毒變異仍不斷演化,公司正力爭相關產品的早日獲批上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account